Past, Current, and Future of Immunotherapies for Prostate Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate CancerBreaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusSequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International PublicationsSafety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsOncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease VirusOn the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsEffective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsCombination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsOncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusIMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de